Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 4/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20962640 | 0.82 | ALDH1A1 (0.48) | KDM4ECYP17A1CYP3A4GFERSIGMAR1 | |
| SCHEMBL18390558 | 0.82 | CHKA (0.50) | KDM4ECYP17A1CYP3A4GFERSIGMAR1 | |
| SCHEMBL22642426 | 0.81 | SIGMAR1 (0.47) | KDM4ECYP17A1CYP3A4GFERSIGMAR1 | |
| SCHEMBL20412747 | 0.81 | CHRNB2 (0.52) | KDM4ECYP17A1CYP3A4GFERSIGMAR1 | |
| SCHEMBL17828171 | 0.79 | ACHE (0.54) | KDM4EACHEHRH3HTR7 | |
| SCHEMBL17121360 | 0.79 | ACHE (0.50) | KDM4EPOLBACHEHRH3HTR7 | |
| SCHEMBL12424413 | 0.79 | ACHE (0.50) | ACHEHRH3HTR7CYP17A1CYP3A4 | |
| SCHEMBL17108785 | 0.79 | ACHE (0.50) | KDM4EACHEHRH3HTR7 | |
| SCHEMBL18390584 | 0.78 | SIGMAR1 (0.44) | KDM4EHRH3CYP17A1CYP3A4GFER | |
| SCHEMBL12013920 | 0.78 | SIGMAR1 (0.70) | KDM4EPOLBACHEHTR7SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| EP-3042900-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | Fujifilm Corporation (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | KDM4E 2666/4885POLB 4001/4885ACHE 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.